The Aurum Institute Tembisa Clinical Research Centre
Welcome,         Profile    Billing    Logout  
 4 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sebe, Modulakgotla A
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
NCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed
2
122
RoW
Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg, Delamanid + Bedaquiline + OPC-167832 90 mg, RHEZ
Otsuka Pharmaceutical Development & Commercialization, Inc., Bill and Melinda Gates Foundation
Pulmonary TB
04/24
05/24

Download Options